Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

Health insurers will not be covering the cost of a new obesity medication coming on to the market in Ireland. Mounjaro, a ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Conagra adds an ‘On Track’ badge on packaging for 26 of its Healthy Choice frozen meals that call out GLP-1 ...

Several small biotechs working on new treatments for weight loss believe that developing therapies with mechanism of actions not seen with current drugs, such as those from Novo Nordisk (NVO) and Eli ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

The luster is starting to wear off GLP-1 weight-loss drugs including Wegovy and Ozempic as more clinicians warn patients ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.